Truist Cuts Exponent Price Target to $90 While Reaffirming Buy Rating
Truist Securities on 2 November lowered its 12-month price objective for engineering and scientific consulting firm Exponent, Inc. (NASDAQ: EXPO) to $90 from $100 but reiterated a Buy recommendation, according to market updates circulated to clients. The brokerage said the company’s specialized work in failure analysis could see stronger demand as artificial-intelligence applications proliferate, yet it […]